Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 347

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

Open access
Davies, Jane C, Cunningham, Steve, Harris, William T, Lapey, Allen, Regelmann, Warren E, Sawicki, Gregory S, Southern, Kevin W, Robertson, Sarah, Green, Yulia, Cooke, Jon, Rosenfeld, Margaret·2016·The Lancet Respiratory Medicine

Abstract

Background Ivacaftor is a safe, effective treatment for cystic fibrosis (CF) in patients aged ≥6 years with a CFTR gating mutation. This open-label, multicenter, phase 3 study assessed ivacaftor in children aged 2–5 years. Methods Children aged 2–5 years with a CFTR gating mutation received ivacaftor (<14 kg: 50 mg every 12 hours; ≥14 kg: 75 mg every 12 hours) for 4 days (Part A; n=9) or 24 weeks (Part B; n=34). Primary outcomes were pharmacokinetics (PK) and safety. Other markers of disease were also evaluated. Findings Ivacaftor PK was similar to that reported in adults. Common adverse events in Part B included cough (n=19; 55·9%) and vomiting (n=10; 29·4%). Five patients (15%) experienced liver function test (LFT) elevations >8× ULN (study drug interrupted, n=4; study discontinuation, n=1). At week 24, sweat chloride improved on average by −46·9 mmol (SD 26·2, p<0·0001), BMI z-score by 0·4 (SD 0·4, p<0·0001), fecal elastase by 99·8 (138·4) μg/g (p=0·0009) and immunoreactive trypsinogen by −20·7 ng/mL (SD 24·0, p=0.0002). Interpretation Ivacaftor appears safe and beneficial in young CF children with a gating mutation followed for 24 weeks. The safety profile was similar to that seen in older CF patients, although the frequency of LFT elevations suggests consideration of more frequent monitoring in younger children, particularly those with a history of elevated LFTs. Improvements in sweat chloride and nutritional parameters, with a suggestion of enhanced pancreatic function were observed. Funding Vertex Pharmaceuticals Incorporated www.clinicaltrials.gov identifier:

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(15)00545-7

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 347

Metadata

Authors
Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S., Green, Y., Cooke, J., & Rosenfeld, M.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2016-02
Volume
4
Issue
2
Pages
107-115
ISSN
2213-2600 (ISSN-L)
OpenAlex
W2254054106
Cited by
347
References
25
FWCI
29.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. https://app.cochat.ai/papers/10.1016/s2213-2600(15)00545-7
The paper
Davies, J. C., Cunningham, S., Harris, W. T., Lapey, A., Regelmann, W. E., Sawicki, G. S., Southern, K. W., Robertson, S., Green, Y., Cooke, J., & Rosenfeld, M. (2016). Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(15)00545-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.